<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Gastroenterol Res Pract</journal-id><journal-id journal-id-type="iso-abbrev">Gastroenterol Res Pract</journal-id><journal-id journal-id-type="publisher-id">GRP</journal-id><journal-title-group><journal-title>Gastroenterology Research and Practice</journal-title></journal-title-group><issn pub-type="ppub">1687-6121</issn><issn pub-type="epub">1687-630X</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4346691</article-id><article-id pub-id-type="doi">10.1155/2015/896560</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>From Molecular Classification to Targeted Therapeutics: The Changing Face of Systemic Therapy in Metastatic Gastroesophageal Cancer </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9983-8641</contrib-id><name><surname>Murphy</surname><given-names>Adrian</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kelly</surname><given-names>Ronan J.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Upper Aerodigestive Malignancies Division, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA</aff><aff id="I2"><sup>2</sup>Gastroesophageal Cancer Therapeutics Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room G93, Baltimore, MD 21231, USA</aff><author-notes><corresp id="cor1">*Ronan J. Kelly: <email>rkelly25@jhmi.edu</email></corresp><fn fn-type="other"><p><text><SENT sid="1" pm="."><plain>Academic Editor: Antoni Castells </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="ppub"><year>2015</year></pub-date><pub-date pub-type="epub"><day>17</day><month>2</month><year>2015</year></pub-date><volume>2015</volume><elocation-id>896560</elocation-id><history><date date-type="received"><day>10</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>15</day><month>1</month><year>2015</year></date></history><permissions><copyright-statement>Copyright © 2015 A. Murphy and R. J. Kelly.</copyright-statement><copyright-year>2015</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Histological classification of adenocarcinoma or squamous cell carcinoma for esophageal cancer or using the Lauren classification for intestinal and diffuse type gastric cancer has limited clinical utility in the management of advanced disease. </plain></SENT>
<SENT sid="3" pm="."><plain>Germline mutations in E-cadherin (CDH1) or mismatch repair genes (Lynch syndrome) were identified many years ago but given their rarity, the identification of these molecular alterations does not substantially impact treatment in the advanced setting. </plain></SENT>
<SENT sid="4" pm="."><plain>Recent molecular profiling studies of upper GI tumors have added to our knowledge of the underlying biology but have not led to an alternative classification system which can guide clinician's therapeutic decisions. </plain></SENT>
<SENT sid="5" pm="."><plain>Recently the Cancer Genome Atlas Research Network has proposed four subtypes of gastric cancer dividing tumors into those positive for Epstein-Barr virus, microsatellite unstable tumors, genomically stable tumors, and tumors with chromosomal instability. </plain></SENT>
<SENT sid="6" pm="."><plain>Unfortunately to date, many phase III clinical trials involving molecularly targeted agents have failed to meet their survival endpoints due to their use in unselected populations. </plain></SENT>
<SENT sid="7" pm="."><plain>Future clinical trials should utilize molecular profiling of individual tumors in order to determine the optimal use of targeted therapies in preselected patients. </plain></SENT>
</text></SecTag></p></abstract></article-meta></front><body><SecTag type="INTRO"><sec id="sec1"><title><text><SENT sid="8" pm="."><plain>1. </plain></SENT>
<SENT sid="9" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="10" pm="."><plain>While the incidence of gastric cancer is decreasing in the United States, the rates of esophageal cancer are increasing. </plain></SENT>
<SENT sid="11" pm="."><plain>In 2014 it is anticipated that 22,220 and 18,170 patients will be newly diagnosed with gastric cancer and esophageal cancer, respectively, while 26,440 men and women will die as a result of upper gastrointestinal (GI) tumors [1]. </plain></SENT>
<SENT sid="12" pm="."><plain>Gastroesophageal cancer remains endemic in many parts of the world with an estimated new cancer incidence of 1,471,000 or 11.6% of the global cancer burden and a death rate annually of 1,144,000 people or 15.1% of cancer-related deaths worldwide. </plain></SENT>
<SENT sid="13" pm="."><plain>Taken together, esophageal cancer and gastric cancer are second only to lung cancer in incidence and in mortality [2]. </plain></SENT>
<SENT sid="14" pm="."><plain>Despite these figures, there has been a dearth of scientific breakthroughs in these tumor types which have resulted in significant survival advantages. </plain></SENT>
</text></p><p><text><SENT sid="15" pm="."><plain>The location of upper GI tumors in western countries has changed dramatically in recent years. </plain></SENT>
<SENT sid="16" pm="."><plain>Distal gastric cancer, which previously predominated, has become uncommon, whereas the incidence of tumors of the gastric cardia and gastroesophageal junction has increased dramatically. </plain></SENT>
<SENT sid="17" pm="."><plain>Prior to the 1970s, distal esophageal adenocarcinomas were uncommon, representing 0.8–3.7% of esophageal cancers [3]. </plain></SENT>
<SENT sid="18" pm="."><plain>Over the past three decades, there has been a sevenfold increase in the incidence of esophageal adenocarcinoma among US white males, now accounting for more than half of the cases of esophageal cancer. </plain></SENT>
<SENT sid="19" pm="."><plain>Through the 1980s, the increases in the rates of these tumors have been on the order of 5–10% per year, a faster pace than for virtually any other cancer in the United States [3]. </plain></SENT>
<SENT sid="20" pm="."><plain>This has been attributed to declining chronic infection rates by Helicobacter pylori and an increased incidence of gastroesophageal reflux disease and obesity [4–6]. </plain></SENT>
</text></p></sec></SecTag><sec id="sec2"><title><text><SENT sid="21" pm="."><plain>2. </plain></SENT>
<SENT sid="22" pm="."><plain>Cytotoxic Chemotherapy for Gastroesophageal Cancer </plain></SENT>
</text></title><p><text><SENT sid="23" pm="."><plain>The treatment of metastatic gastroesophageal junction and gastric cancer has been poorly investigated and at present there is no single chemotherapeutic regimen that is considered standard first-line treatment. </plain></SENT>
<SENT sid="24" pm="."><plain>Various combinations of platinum-based doublets and triplets have been prescribed depending on patient performance status and physician preference. </plain></SENT>
<SENT sid="25" pm="."><plain>Current therapy for advanced disease is limited and survival rarely exceeds one year despite aggressive treatment with modern chemotherapy. </plain></SENT>
<SENT sid="26" pm="."><plain>Second-line regimens have, until recently, been considered ineffective. </plain></SENT>
<SENT sid="27" pm="."><plain>A number of different drugs (e.g., alkylating agents, platinum compounds, 5 FU, and taxanes) are available for the treatment of gastroesophageal cancer but no means of selecting therapy based upon the biology of the tumor is currently available (Table 1). </plain></SENT>
<SENT sid="28" pm="."><plain>HER2 status remains the only validated molecular marker which influences clinician decision-making in the metastatic setting. </plain></SENT>
<SENT sid="29" pm="."><plain>At present the combination of a platinum and fluorouracil, either alone or in combination with a third drug such as epirubicin or a taxane, constitutes the most effective treatment option in the first-line metastatic setting [7]. </plain></SENT>
<SENT sid="30" pm="."><plain>Standard first-line options include DCF (docetaxel, cisplatin, and 5 FU), ECF/EOX (epirubicin, cisplatin/oxaliplatin, and 5 FU/capecitabine), or FOLFOX (5 FU, oxaliplatin) [8–10]. </plain></SENT>
<SENT sid="31" pm="."><plain>Additional FDA approved 2nd line agents include docetaxel, paclitaxel, and irinotecan [11–14]. </plain></SENT>
</text></p></sec><sec id="sec3"><title><text><SENT sid="32" pm="."><plain>3. </plain></SENT>
<SENT sid="33" pm="."><plain>Molecular Classification of Gastric Cancer </plain></SENT>
</text></title><p><text><SENT sid="34" pm="."><plain>Molecular profiling studies have been performed using gene expression or DNA sequencing and have identified distinctive molecular signatures which may predict responsiveness to systemic therapies. </plain></SENT>
<SENT sid="35" pm="."><plain>Earlier studies in gastric cancer concentrated on molecular signatures which characterized the processes of tumorigenesis. </plain></SENT>
<SENT sid="36" pm="."><plain>Microarray-based gene expression profiling identified characteristic expression patterns which readily discern premalignant from malignant tissues [15]. </plain></SENT>
<SENT sid="37" pm="."><plain>Chronic gastritis tissue expressed a marked mitochondrial gene expression signature possibly as a response to H. pylori infection, for example, NDUF (NADH dehydrogenase), whereas intestinal metaplastic tissue expressed a more transformed phenotype including many intestinal differentiation genes which were not expressed in tumor tissues, for example, CDX1, MYO1A, and villin A. Later studies examined whether the molecular signature could predict sensitivity to chemotherapy [16]. </plain></SENT>
<SENT sid="39" pm="."><plain>Genomic subtypes (intestinal and diffuse) identified from in vitro studies in gastric cancer and validated in primary tumors were found to be prognostic of survival and had the ability to predict sensitivity to 5 FU and/or platinum agents. </plain></SENT>
<SENT sid="40" pm="."><plain>It was possible to detect these subtypes by immunohistochemical analysis of LGALS4 and CDH17 expression. </plain></SENT>
<SENT sid="41" pm="."><plain>These studies may ultimately identify predictive biomarkers allowing physicians to personalize chemotherapy selection in gastric cancer. </plain></SENT>
</text></p><p><text><SENT sid="42" pm="."><plain>Molecular profiling has been extended in an attempt to predict responsiveness to targeted therapies [17]. </plain></SENT>
<SENT sid="43" pm="."><plain>Gene expression patterns were analyzed with advanced bioinformatics tools to identify molecular signature subtypes which predicted response to inhibitors of the PI3K/Akt/mTOR pathway. </plain></SENT>
</text></p><p><text><SENT sid="44" pm="."><plain>The Cancer Genome Atlas Research Network (TCGA) has recently performed a comprehensive molecular characterization of gastric tumors from 295 patients who had not been treated with prior chemotherapy or radiotherapy [18]. </plain></SENT>
<SENT sid="45" pm="."><plain>Detailed genetic analysis was performed using array-based somatic copy number analysis, whole-exome sequencing, array-based DNA methylation profiling, mRNA sequencing, microRNA sequencing, and reverse-phase protein arrays. </plain></SENT>
<SENT sid="46" pm="."><plain>It has proposed four subtypes (Figure 1(a)): (1) tumors positive for Epstein-Barr virus, (2) microsatellite unstable tumors, (3) genomically stable tumors, and (4) tumors with chromosomal instability. </plain></SENT>
</text></p><p><text><SENT sid="47" pm="."><plain>EBV-associated tumors were shown to have a higher prevalence of DNA hypermethylation than any other tumor reported by the TCGA. </plain></SENT>
<SENT sid="48" pm="."><plain>All EBV-positive tumors displayed CDKN2A promoter hypermethylation and 80% had PIK3CA mutations. </plain></SENT>
<SENT sid="49" pm="."><plain>In addition, PD-L1/2 expression was elevated in EBV-positive tumors suggesting a role of targeted immunotherapy in this subset of gastric tumors. </plain></SENT>
<SENT sid="50" pm="."><plain>Microsatellite unstable (MSI) tumors generally lacked targetable amplifications although mutations in PIK3CA, HER2, HER3, and EGFR were noted. BRAF (V600E) mutations were not seen in gastric MSI tumors unlike its counterpart in colorectal cancer. </plain></SENT>
<SENT sid="51" pm="."><plain>Genomically stable gastric tumors are enriched for the diffuse histological variant and have newly described mutations in RHOA which acts through several effectors to control actin-myosin-dependent cell contractility and motility. </plain></SENT>
<SENT sid="52" pm="."><plain>In addition, a recurrent interchromosomal translocation (between CLDN18 and ARHGAP26) implicated in cell motility was found in genomically stable gastric tumors. </plain></SENT>
<SENT sid="53" pm="."><plain>Almost half of gastric tumors demonstrated chromosomal instability which was characterized by marked aneuploidy and focal amplification of receptor tyrosine kinases such as amplification of VEGFA and frequent amplifications of cell cycle mediators (CCNE1, CCND1, and CDK6). </plain></SENT>
<SENT sid="54" pm="."><plain>This study has considerably added to our knowledge of the molecular subtyping of gastric cancer and hopefully will permit improved patient selection for clinical trials in the future. </plain></SENT>
</text></p></sec><sec id="sec4"><title><text><SENT sid="55" pm="."><plain>4. </plain></SENT>
<SENT sid="56" pm="."><plain>Molecular Classification of Esophageal Cancer </plain></SENT>
</text></title><p><text><SENT sid="57" pm="."><plain>Chromosomal aberrations leading to gene dysregulation have been reported in esophageal cancer including amplifications on 8q and 17q mapped to the C-MYC and ERBB2 oncogenes [19, 20]. </plain></SENT>
</text></p><p><text><SENT sid="58" pm="."><plain>The role of MYC in the pathogenesis of esophageal cancer is not well defined and additional research is required. </plain></SENT>
<SENT sid="59" pm="."><plain>Loss of heterozygosity of TP53 occurs in greater than 50% of cases of esophageal cancer and is considered a strong predictor of disease progression [21–23]. </plain></SENT>
<SENT sid="60" pm="."><plain>In addition, two genes reported to have homozygous deletions in esophageal cancer are p16/CDKN2A and FHIT [24]. </plain></SENT>
<SENT sid="61" pm="."><plain>Abeloff et al. performed an integrative analysis of array-comparative genomic hybridization and matched gene expression profiling to reveal novel genes with prognostic significance in esophageal adenocarcinomas [25]. </plain></SENT>
<SENT sid="62" pm="."><plain>The authors identified 17 common regions (&gt;5%) of gain and 11 common regions of losses in 56 resected specimens with associated long-term clinical follow-up data. </plain></SENT>
<SENT sid="63" pm="."><plain>Novel regions identified included loci 11p13 and 21q21.2. </plain></SENT>
</text></p><p><text><SENT sid="64" pm="."><plain>Genes with high copy number and expression correlations included two deletions (p16/CDKN2, MBNL1) and four gains (EGFR, WT1, NEIL2, and MTMR9). </plain></SENT>
<SENT sid="65" pm="."><plain>These genes individually (P &lt; 0.06) and collectively had prognostic significance (P = 0.008). </plain></SENT>
<SENT sid="66" pm="."><plain>A host of additional genes have been studied for mutations in esophageal cancer, but in most of these single gene studies, very few mutations have been identified. </plain></SENT>
<SENT sid="67" pm="."><plain>In an effort to perform a comprehensive evaluation of all coding regions for mutations, Agrawal et al. performed a comprehensive study of esophageal cancer exomes including both adenocarcinomas and squamous cell carcinomas [26]. </plain></SENT>
<SENT sid="68" pm="."><plain>Inactivating mutations of NOTCH1 were identified in 21% of esophageal squamous cell carcinomas but not in adenocarcinomas. </plain></SENT>
</text></p><p><text><SENT sid="69" pm="."><plain>Dulak et al. conducted an analysis of somatic copy-number alterations using high-density genomic profiling arrays in 296 esophageal and gastric cancers [27]. </plain></SENT>
<SENT sid="70" pm="."><plain>Amplified genes were noted in 37% of gastric/esophageal tumors, including ERBB2, FGFR1, FGFR2, EGFR, and MET, suggesting that some of these may be viable targets in esophageal cancer although amplification of some of these may be more prevalent in gastric tumors. </plain></SENT>
</text></p></sec><sec id="sec5"><title><text><SENT sid="71" pm="."><plain>5. </plain></SENT>
<SENT sid="72" pm="."><plain>Molecular Targets in Advanced Disease </plain></SENT>
</text></title><sec id="sec5.1"><title><text><SENT sid="73" pm="."><plain>5.1. </plain></SENT>
<SENT sid="74" pm="."><plain>HER2 </plain></SENT>
</text></title><p><text><SENT sid="75" pm="."><plain>HER2 is a protooncogene which is encoded by ERBB2 found on chromosome 17. </plain></SENT>
<SENT sid="76" pm="."><plain>It belongs to the HER family of membrane-bound receptor tyrosine kinases which is responsible for the initiation of cell signaling pathways via phosphoinositide 3-kinase, phospholipase C, and mitogen-activated protein kinase [28]. </plain></SENT>
<SENT sid="77" pm="."><plain>While originally known for its effects in breast cancer, HER2 overexpression has been shown to result in worse prognosis in gastric cancer [29, 30] although there are conflicting studies which suggest that it has no effect or is even beneficial in terms of prognosis [31, 32]. </plain></SENT>
</text></p><p><text><SENT sid="78" pm="."><plain>The TOGA trial was a phase III prospective trial which demonstrated the benefits of adding trastuzumab, a humanized monoclonal antibody targeting HER2, to a platinum-based doublet in the presence of HER2 IHC 2+ or FISH amplified metastatic gastroesophageal or gastric cancer [33]. </plain></SENT>
<SENT sid="79" pm="."><plain>In this trial, 594 patients were randomly assigned to study treatment (trastuzumab plus chemotherapy, n = 298; chemotherapy alone, n = 296), of whom 584 were included in the primary analysis (n = 294; n = 290). </plain></SENT>
<SENT sid="80" pm="."><plain>Median overall survival was 13.8 months (95% CI 12–16 months) in those assigned to trastuzumab plus chemotherapy compared with 11.1 months in those assigned to chemotherapy alone (hazard ratio 0.74; 95% CI 0.60–0.91; P = 0.0046). </plain></SENT>
<SENT sid="81" pm="."><plain>Unfortunately only 15–20% of patients with esophageal or gastroesophageal tumors are HER2 positive [32] and intestinal-type disease and tumors at the gastroesophageal junction and proximal stomach have higher HER2 expression [33]. </plain></SENT>
<SENT sid="82" pm="."><plain>The benefit of trastuzumab was confined to those with IHC 2+/3+ and FISH positivity. </plain></SENT>
</text></p><p><text><SENT sid="83" pm="."><plain>The practice of maintenance trastuzumab and continuing trastuzumab until evidence of disease progression are commonplace in the management of breast cancer [34, 35] but there is a lack of data indicating that this is a successful strategy in gastroesophageal cancer although a Japanese trial is currently investigating this approach [36]. </plain></SENT>
<SENT sid="84" pm="."><plain>The development of resistance to trastuzumab has prompted investigating alternative drugs which target HER2. </plain></SENT>
<SENT sid="85" pm="."><plain>Lapatinib is an oral dual tyrosine kinase inhibitor which targets EGFR and HER2 domains resulting in blocked autophosphorylation and downstream signaling [37]. </plain></SENT>
<SENT sid="86" pm="."><plain>The phase III TYTAN study compared paclitaxel with or without lapatinib in HER2 positive gastric cancer in the second-line setting in Asian patients [38]. </plain></SENT>
<SENT sid="87" pm="."><plain>Median overall survival was 11 months with paclitaxel plus lapatinib compared to 8.9 months with paclitaxel alone (P = 0.1044). </plain></SENT>
<SENT sid="88" pm="."><plain>There was also no significant difference in PFS or TTP. </plain></SENT>
<SENT sid="89" pm="."><plain>Pertuzumab is a monoclonal antibody which binds to HER2 preventing its dimerization with other HER receptors [39]. </plain></SENT>
<SENT sid="90" pm="."><plain>It is currently the subject of a phase III trial (JACOB) comparing pertuzumab/trastuzumab + chemotherapy to pertuzumab + chemotherapy [40]. </plain></SENT>
<SENT sid="91" pm="."><plain>Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate combining trastuzumab and DM1 which is a cytotoxic/microtubule polymerization agent [41]. </plain></SENT>
<SENT sid="92" pm="."><plain>T-DM1 binds to the HER2 receptor resulting in internalization of the DM1-receptor complex which results in the inhibition of cell division/growth and ultimately cell death [42]. </plain></SENT>
<SENT sid="93" pm="."><plain>The ongoing GATSBY trial is currently investigating T-DM1 versus a taxane in patients with previously treated HER2-positive metastatic or locally advanced gastric cancer [43]. </plain></SENT>
</text></p></sec><sec id="sec5.2"><title><text><SENT sid="94" pm="."><plain>5.2. </plain></SENT>
<SENT sid="95" pm="."><plain>EGFR </plain></SENT>
</text></title><p><text><SENT sid="96" pm="."><plain>The epidermal growth factor receptor (EGFR) is known to play an important role in the initiation of signaling transduction cascades via phosphorylation of numerous cellular proteins [44]. </plain></SENT>
<SENT sid="97" pm="."><plain>A meta-analysis of 7 studies concluded that EGFR expression correlates with decreased survival in gastric cancer [45]. </plain></SENT>
<SENT sid="98" pm="."><plain>In addition, preclinical data suggest that a subset of gastric cancers (20%) with EGFR amplification and overexpression can respond to cetuximab therapy [46]. </plain></SENT>
<SENT sid="99" pm="."><plain>Cetuximab is a monoclonal antibody directed against the EGFR receptor and was shown to improve outcomes in kras wild-type metastatic colorectal cancer [47]. </plain></SENT>
<SENT sid="100" pm="."><plain>The EXPAND study was a phase III trial which studied capecitabine and cisplatin with or without cetuximab in the first line setting in advanced gastric cancer [48]. </plain></SENT>
<SENT sid="101" pm="."><plain>Median PFS for chemotherapy/cetuximab was 4.4 months versus 5.6 months for those who received chemotherapy alone (HR = 1.09, 95% CI 0.92–1.29, P = 0.32). </plain></SENT>
<SENT sid="102" pm="."><plain>Adding cetuximab to this chemotherapy combination also did not improve overall survival (9.4 months in both arms, HR = 1.0, 95% CI 0.87–1.17, P = 0.95). </plain></SENT>
<SENT sid="103" pm="."><plain>The phase III REAL-3 trial compared EOX (epirubicin, oxaliplatin, and capecitabine) with or without panitumumab, a fully human antibody targeting the EGFR receptor [49]. </plain></SENT>
<SENT sid="104" pm="."><plain>Median overall survival in the chemotherapy group was 11.3 months compared to chemotherapy + panitumumab which was 8.8 months (HR = 1.37, 95% CI 1.07–1.76, P = 0.013). </plain></SENT>
<SENT sid="105" pm="."><plain>An additional EGFR-targeting drug matuzumab also gave disappointing results in advanced esophagogastric cancer [50]. </plain></SENT>
<SENT sid="106" pm="."><plain>A combination of ECX chemotherapy/matuzumab failed to improve overall survival (9.4 months for matuzumab group compared with 12.2 months, HR = 1.02, 95% CI 0.61–1.70, P = 0.945). </plain></SENT>
</text></p><p><text><SENT sid="107" pm="."><plain>While these results may highlight the lack of importance of the EGFR pathway in esophagogastric cancer, it is important to note that many negative studies were conducted in an unselected population which may explain their negative results. </plain></SENT>
</text></p></sec><sec id="sec5.3"><title><text><SENT sid="108" pm="."><plain>5.3. </plain></SENT>
<SENT sid="109" pm="."><plain>C-MET </plain></SENT>
</text></title><p><text><SENT sid="110" pm="."><plain>C-MET has been proposed as a promising new target in advanced disease and a number of phase III trials are now in progress combining MET inhibitors with chemotherapy in the first-line setting for metastatic gastroesophageal cancer. </plain></SENT>
<SENT sid="111" pm="."><plain>C-MET is a receptor tyrosine kinase which interacts with its ligand HGF (hepatocyte growth factor) [51]. </plain></SENT>
<SENT sid="112" pm="."><plain>It has been found to be dysregulated in gastric cancers and is involved with tumor proliferation, invasion, and angiogenesis and has antiapoptotic functions in cancer cells [52, 53]. </plain></SENT>
<SENT sid="113" pm="."><plain>Tumors which harbor high C-MET expression are more likely to have poor survival rates [54]. </plain></SENT>
<SENT sid="114" pm="."><plain>In a recently reported phase II study, the anti-HGF monoclonal antibody rilotumumab was combined with chemotherapy with progression-free survival (PFS) as the primary endpoint. </plain></SENT>
<SENT sid="115" pm="."><plain>PFS was 5.7 months in rilotumumab treatment arms versus 4.2 months in the placebo group (HR = 0.60, 80% CI 0.45–0.79; P = 0.016) [55]. </plain></SENT>
<SENT sid="116" pm="."><plain>Unfortunately a significant increase in overall survival was not reported although a phase III study is ongoing comparing rilotumumab alone or in combination with cisplatin/capecitabine in the first-line setting [56]. </plain></SENT>
<SENT sid="117" pm="."><plain>Tivantinib, although originally regarded as a c-MET inhibitor, has been shown to function independently of the c-MET pathway. </plain></SENT>
<SENT sid="118" pm="."><plain>Studies on lung cancer cell lines have shown that tivantinib does not inhibit cellular MET activity or downstream phosphorylation of Akt or ERK 1/2 in met-dependent cell lines [57]. </plain></SENT>
<SENT sid="119" pm="."><plain>Another preclinical study has shown that tivantinib inhibits microtubule polymerization independent of c-MET [58]. </plain></SENT>
<SENT sid="120" pm="."><plain>However, tivantinib has shown promising efficacy as a single agent in a phase II study meriting further study in combination with chemotherapy in a phase III design [59]. </plain></SENT>
</text></p></sec></sec><sec id="sec6"><title><text><SENT sid="121" pm="."><plain>6. </plain></SENT>
<SENT sid="122" pm="."><plain>Antiangiogenic Therapy </plain></SENT>
</text></title><p><text><SENT sid="123" pm="."><plain>Angiogenesis is largely recognized as an important aspect of tumorigenesis and preliminary clinical studies suggested a clinical benefit in the addition of bevacizumab, a monoclonal antibody against VEGF-A, in combination with chemotherapy in gastric cancer [60, 61]. </plain></SENT>
<SENT sid="124" pm="."><plain>The failure of bevacizumab to improve overall survival in the phase III AVAGAST trial was a disappointing development although interestingly it did appear from a subset analysis that a western population may derive some benefit [62, 63]. </plain></SENT>
<SENT sid="125" pm="."><plain>When subset analyses were performed in the AVAGAST trial, it appeared that those with type 3 (distal nondiffuse) gastric cancer and those from European/American populations derived more benefit from bevacizumab than other gastric cancer subtypes or patients from Asian/Pacific populations. </plain></SENT>
<SENT sid="126" pm="."><plain>The VEGFR-2 (vascular endothelial growth factor receptor-2) antagonist ramucirumab, as reported in the REGARD trial, demonstrated modest activity in patients with advanced gastric or gastroesophageal junction adenocarcinoma who had disease progression after first-line platinum-containing or fluoropyrimidine-containing chemotherapy [64]. </plain></SENT>
<SENT sid="127" pm="."><plain>Median overall survival was 5.2 months (IQR 2.3–9.9) in patients in the ramucirumab group and 3.8 months (IQR 1.7–7.1) in those in the placebo group (HR = 0.776, 95% CI 0.603–0.998; P = 0.047). </plain></SENT>
<SENT sid="128" pm="."><plain>The subsequently reported RAINBOW trial investigated paclitaxel ± ramucirumab in patients with metastatic GEJ or gastric adenocarcinoma who had disease progression on or within 4 months after first-line platinum- and fluoropyrimidine-based combination therapy [65]. </plain></SENT>
<SENT sid="129" pm="."><plain>The primary endpoint was overall survival (OS). </plain></SENT>
<SENT sid="130" pm="."><plain>Median OS was 9.63 months for ramucirumab + paclitaxel compared to 7.36 months for paclitaxel alone (HR = 0.807, 95% CI 0.678–0.962, P = 0.017). </plain></SENT>
<SENT sid="131" pm="."><plain>Based on these results the combination of ramucirumab + paclitaxel is expected to become a standard of care treatment regimen in the second-line setting for metastatic upper GI tumors. </plain></SENT>
<SENT sid="132" pm="."><plain>The success of ramucirumab in the 2nd line setting has prompted its clinical investigation in the first line setting. </plain></SENT>
<SENT sid="133" pm="."><plain>When ramucirumab was combined with FOLFOX in the first-line setting, it did not improve median progression-free survival (6.4 versus 6.7 months, HR = 0.98, 95% CI 0.69–1.37, P = 0.89) or overall survival (11.7 versus 11.5 months, HR = 1.08, 95% CI 0.73–1.58) in patients with advanced gastric/GE junction tumors [66]. </plain></SENT>
<SENT sid="134" pm="."><plain>Clinical trials investigating alternative combinations of chemotherapy with ramucirumab in the first-line setting are ongoing. </plain></SENT>
</text></p><p><text><SENT sid="135" pm="."><plain>Prior to the success of ramucirumab, tyrosine kinase inhibitors had been explored in their roles as antiangiogenic agents in the treatment of esophagogastric tumors. </plain></SENT>
<SENT sid="136" pm="."><plain>Several tyrosine kinase inhibitors with known antiangiogenic activity are already in use for other tumor types, for example, renal cell cancer. </plain></SENT>
<SENT sid="137" pm="."><plain>Sunitinib was studied in a phase II trial in patients with advanced gastric or GE junction tumors who had progressed on chemotherapy [67]. </plain></SENT>
<SENT sid="138" pm="."><plain>The clinical benefit rate was 7.7% with 32.1% of patients exhibiting disease stability. </plain></SENT>
<SENT sid="139" pm="."><plain>By intent-to-treat analysis, median overall survival was 6.8 months (95% CI 4.4–9.7 months). </plain></SENT>
<SENT sid="140" pm="."><plain>The addition of docetaxel to sunitinib resulted in a higher objective response rate (41.1% versus 14.3%, P = 0.02) although this study did not meet its primary endpoint of prolonging time-to-progression [68]. </plain></SENT>
<SENT sid="141" pm="."><plain>Sorafenib, a multitarget TKI of BRAF, VEGF, and PDGFR, was combined with oxaliplatin in a phase II trial in patients who had progressed on first-line cisplatin/fluoropyrimidine chemotherapy [69]. </plain></SENT>
<SENT sid="142" pm="."><plain>This study did not meet its primary endpoint of efficacy and showed median PFS of 3 months (95% CI 2.3–4.1 months) and median overall survival of 6.5 months (95% CI 5.2–9.6 months). </plain></SENT>
</text></p></sec><sec id="sec7"><title><text><SENT sid="143" pm="."><plain>7. </plain></SENT>
<SENT sid="144" pm="."><plain>Cancer Cell Stemness </plain></SENT>
</text></title><p><text><SENT sid="145" pm="."><plain>The characteristic of cancer cells' ability to grow indefinitely has led to the theory that they share common underlying mechanisms with stem cells [70]. </plain></SENT>
<SENT sid="146" pm="."><plain>BB1608 is an orally available cancer cell stemness inhibitor whose exact target has not been elucidated [71]. </plain></SENT>
<SENT sid="147" pm="."><plain>It has been shown to inhibit the Stat3, β-catenin, and Nanog pathways. </plain></SENT>
<SENT sid="148" pm="."><plain>To date, a phase Ib study has been conducted combining BB1608 and paclitaxel in advanced cancers and of 5 patients enrolled with refractory gastric/GEJ tumors, 2 had partial responses, 1 had stable disease with 25% regression, and 2 had prolonged disease stability ≥24 weeks. </plain></SENT>
</text></p></sec><sec id="sec8"><title><text><SENT sid="149" pm="."><plain>8. </plain></SENT>
<SENT sid="150" pm="."><plain>Hedgehog Inhibitors </plain></SENT>
</text></title><p><text><SENT sid="151" pm="."><plain>The sonic hedgehog (SHH) pathway is crucial for normal cell differentiation and aberrant function affects gastric cell proliferation, migration, and invasion [72]. </plain></SENT>
<SENT sid="152" pm="."><plain>A phase II trial combined vismodegib (SHH pathway inhibitor) with FOLFOX in patients with advanced gastric and GE junction tumors [73]. </plain></SENT>
<SENT sid="153" pm="."><plain>Patients were treated in the first-line setting and the primary endpoint of median PFS was not met in the intention-to-treat population (11.5 months for FOLFOX/vismodegib versus 9.3 months for FOLFOX alone, 95% CI 8.5–14.4, P = 0.34). </plain></SENT>
<SENT sid="154" pm="."><plain>However, the expression of CD44, a gastric cancer stem cell marker, was associated with improved survival in the group who received the SHH inhibitor suggesting that SHH inhibition may only be effective in those with high CD44 expression [74]. </plain></SENT>
</text></p></sec><sec id="sec9"><title><text><SENT sid="155" pm="."><plain>9. </plain></SENT>
<SENT sid="156" pm="."><plain>IGFR Targeted Therapy </plain></SENT>
</text></title><p><text><SENT sid="157" pm="."><plain>Insulin-like growth factors (IGF) are potent hormones which regulate cell proliferation, differentiation, and survival via endocrine, paracrine, and autocrine pathways [75]. </plain></SENT>
<SENT sid="158" pm="."><plain>Increased IGF-1R signaling, a ubiquitously expressed tyrosine kinase receptor, is associated with downstream activation of MAPK/PI3K and is supportive for tumor growth [76]. </plain></SENT>
<SENT sid="159" pm="."><plain>Cixutumumab, a fully human IgG1 monoclonal antibody specifically targeting IGF-1R, has shown promising antiproliferative activity in vitro and clinically, in soft tissue sarcomas [77]. </plain></SENT>
<SENT sid="160" pm="."><plain>Cixutumumab was combined with paclitaxel in metastatic esophageal/GE junction cancer in a randomized phase II study [78]. </plain></SENT>
<SENT sid="161" pm="."><plain>The primary endpoint (PFS) was not met with median PFS reaching 2.6 months for paclitaxel alone and 2.3 months for paclitaxel + cixutumumab (90% CI 2–3.6 months, P = 0.72). </plain></SENT>
</text></p></sec><sec id="sec10"><title><text><SENT sid="162" pm="."><plain>10. </plain></SENT>
<SENT sid="163" pm="."><plain>Plk-1 Targeted Therapy </plain></SENT>
</text></title><p><text><SENT sid="164" pm="."><plain>Human polo-like kinase 1 (Plk-1) plays a pivotal role in mitosis in normal and malignant cells and preclinical studies have highlighted the importance of Plk-1 in tumor development [79, 80]. </plain></SENT>
<SENT sid="165" pm="."><plain>Plk-1 is overexpressed in gastric tumor tissue and is associated with worse prognosis [81]. </plain></SENT>
<SENT sid="166" pm="."><plain>Volasertib (BI 6727) is a potent Plk-1 inhibitor which induces cell cycle arrest and apoptosis and was administered in combination with an angiokinase inhibitor Nintedanib (BIBF 1120) in a phase I dose-escalation study. </plain></SENT>
<SENT sid="167" pm="."><plain>This found that it was well-tolerated and a single patient with gastric cancer achieved a partial response [82]. </plain></SENT>
</text></p></sec><sec id="sec11"><title><text><SENT sid="168" pm="."><plain>11. </plain></SENT>
<SENT sid="169" pm="."><plain>FGFR Therapy </plain></SENT>
</text></title><p><text><SENT sid="170" pm="."><plain>Amplification of the FGFR2 (fibroblast growth factor receptor 2) has been associated with tumorigenesis and results in downstream activation of the MAPK/PI3K pathways [83]. </plain></SENT>
<SENT sid="171" pm="."><plain>The overexpression of members of the FGF family has been associated with tumor progression/metastasis and is associated with poor survival in gastric cancer [84]. </plain></SENT>
<SENT sid="172" pm="."><plain>There is currently a phase II trial investigating the effects of dovitinib, a dual VEGF, and FGFR inhibitor, in combination with docetaxel as second-line chemotherapy in gastric cancer [85]. </plain></SENT>
</text></p></sec><sec id="sec12"><title><text><SENT sid="173" pm="."><plain>12. </plain></SENT>
<SENT sid="174" pm="."><plain>PI3K/mTOR Therapy </plain></SENT>
</text></title><p><text><SENT sid="175" pm="."><plain>The PI3K (phosphatidylinositol 3-kinase) pathway usually becomes activated through growth factor stimulation by EGFR, PDGFR, IGFR, or c-Met [86]. </plain></SENT>
<SENT sid="176" pm="."><plain>Once PI3K is activated, Akt becomes phosphorylated affecting cell cycle progression and angiogenesis and has antiapoptotic effects [87]. </plain></SENT>
<SENT sid="177" pm="."><plain>The mTOR pathway is a central kinase pathway that increases the production of proteins which regulate key cellular processes including metabolism, angiogenesis, and cell growth [88]. </plain></SENT>
<SENT sid="178" pm="."><plain>Phosphorylated mTOR, indicating constitutive activation, has been associated with tumor progression and worse prognosis in gastric cancer patients [89]. </plain></SENT>
<SENT sid="179" pm="."><plain>Genetic alterations affecting the PI3K/Akt/mTOR pathway are frequently found in gastric cancer [90–92]. </plain></SENT>
<SENT sid="180" pm="."><plain>There are several potential approaches to inhibit aberrant PI3K/Akt/mTOR signaling including specifically targeting a single component of the pathway, for example, mTOR inhibitors, or dual inhibitors, for example, dual PI3K/mTOR inhibitors. </plain></SENT>
<SENT sid="181" pm="."><plain>A phase Ib trial has been completed combining a PI3K inhibitor BYL719 with a HSP inhibitor AUY922 in metastatic gastric cancer patients whose tumors are HER2 amplified or who harbor a PI3K mutation [93]. </plain></SENT>
<SENT sid="182" pm="."><plain>Everolimus, an oral mTOR inhibitor, was investigated in advanced gastric cancer in the GRANITE-1 study [94]. </plain></SENT>
<SENT sid="183" pm="."><plain>Patients who had progressed after 1-2 lines of chemotherapy were randomized to receive everolimus or best supportive care (BSC). </plain></SENT>
<SENT sid="184" pm="."><plain>Median overall survival was 5.4 months with everolimus and 4.3 months with BSC (HR = 0.90, 95% CI 0.75–1.08, P = 0.124). </plain></SENT>
<SENT sid="185" pm="."><plain>There are also several ongoing trials comparing everolimus with chemotherapy (paclitaxel, capecitabine, and oxaliplatin) [95, 96]. </plain></SENT>
</text></p></sec><SecTag type="METHODS"><sec id="sec13"><title><text><SENT sid="186" pm="."><plain>13. </plain></SENT>
<SENT sid="187" pm="."><plain>Clinical Trial Design in Gastroesophageal Cancer </plain></SENT>
</text></title><p><text><SENT sid="188" pm="."><plain>Many of the clinical trials involving molecularly targeted agents in gastroesophageal cancer have had initially promising results which do not persist later in larger phase II/III studies. </plain></SENT>
<SENT sid="189" pm="."><plain>Numbers of participants in these trials are small relative to other tumor types (e.g., breast or colon cancer) and this may explain, in part, the negative results. </plain></SENT>
<SENT sid="190" pm="."><plain>However, for the large part, these trials have been conducted in an unselected population. </plain></SENT>
<SENT sid="191" pm="."><plain>Designing clinical trials based on molecularly selected populations whose tumors overexpress a particular molecular marker, makes it more challenging to accrue, but represents a more meaningful approach. </plain></SENT>
<SENT sid="192" pm="."><plain>The PANGEA study (personalized antibodies for gastroesophageal adenocarcinoma) is an example of a trial that will prospectively determine whether assigning patients to targeted therapies based on the molecular profiling of their tumors, will impact median overall survival [97]. </plain></SENT>
<SENT sid="193" pm="."><plain>This innovative study design may represent the future of targeted therapy evaluation in gastroesophageal cancer where a variety of targeted therapies are now available to patients based on the individual molecular biology of their tumor. </plain></SENT>
</text></p></sec></SecTag><SecTag type="CONCL"><sec id="sec14"><title><text><SENT sid="194" pm="."><plain>14. </plain></SENT>
<SENT sid="195" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="196" pm="."><plain>The development of new therapies for advanced gastroesophageal cancer has been slow compared to other common tumors. </plain></SENT>
<SENT sid="197" pm="."><plain>Upper GI tumors represent diverse and heterogeneous diseases with multiple etiological factors including viral and bacterial infection via EBV and Helicobacter pylori, inherited familial syndromes, and other risk factors including diet, smoking, and alcohol consumption. </plain></SENT>
<SENT sid="198" pm="."><plain>Taken together, upper GI tumors are second only to lung cancer in terms of cancer related morbidity. </plain></SENT>
<SENT sid="199" pm="."><plain>In recent years incremental breakthroughs in our understanding of the molecular biology underlying the development of these cancers have taken place and these findings are now being translated into clinical research. </plain></SENT>
<SENT sid="200" pm="."><plain>High density genomic profiling arrays analyzing somatic copy-number alterations in gastroesophageal cancers have identified amplified genes in 37% of tumors, most notably, ERBB2, FGFR1, FGFR2, EGFR, and MET [27]. </plain></SENT>
<SENT sid="201" pm="."><plain>Until recently however the “one-size fits all approach” to enrolling patients on clinical trials has failed in gastroesophageal cancer as it has in other tumor types. </plain></SENT>
</text></p><p><text><SENT sid="202" pm="."><plain>The Cancer Genome Atlas Research Network has recently identified other viable targets and it appears likely that the four molecular subtypes of gastric cancer described in this study should advance clinical research in the years to come. </plain></SENT>
<SENT sid="203" pm="."><plain>In addition to targeted agents there has been a rapid expansion in our understanding of the immune environment changes that occur in these tumors allowing them to avoid immune-editing. </plain></SENT>
<SENT sid="204" pm="."><plain>Future studies may combine targeted therapeutics with immunotherapies such as checkpoint inhibitors. </plain></SENT>
<SENT sid="205" pm="."><plain>Patient selection should be performed in all clinical trials to ensure that molecularly targeted therapies can fulfill their promise in upper GI tumors. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="COMP_INT"><sec sec-type="conflict"><title>Conflict of Interests</title><p>The authors declare that there is no conflict of interests regarding the publication of this paper.</p></sec></SecTag><SecTag type="REF"><ref-list><ref id="B1"><text><SENT sid="206" pm="."><plain>1SiegelR.MaJ.ZouZ.JemalA.Cancer statistics, 2014CA: Cancer Journal for Clinicians201464192910.3322/caac.212082-s2.0-84892805731 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="207" pm="."><plain>2FerlayJ.ShinH.-R.BrayF.FormanD.MathersC.ParkinD. </plain></SENT>
<SENT sid="208" pm="."><plain>M.Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer201012712289329172-s2.0-7804948526310.1002/ijc.2551621351269 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="209" pm="."><plain>3CrewK. </plain></SENT>
<SENT sid="210" pm="."><plain>D.NeugutA. </plain></SENT>
<SENT sid="211" pm="."><plain>I.Epidemiology of upper gastrointestinal malignanciesSeminars in Oncology200431445046410.1053/j.seminoncol.2004.04.0212-s2.0-404314493515297938 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="212" pm="."><plain>4FormanD.An international association between Helicobacter pylori infection and gastric cancer. </plain></SENT>
<SENT sid="213" pm="."><plain>The EUROGAST Study GroupThe Lancet199334188571359136210.1016/0140-6736(93)90938-d2-s2.0-0027176157 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="214" pm="."><plain>5RubensteinJ. </plain></SENT>
<SENT sid="215" pm="."><plain>H.TaylorJ. </plain></SENT>
<SENT sid="216" pm="."><plain>B.Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal refluxAlimentary Pharmacology and Therapeutics201032101222122710.1111/j.1365-2036.2010.04471.x2-s2.0-7824926354120955441 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="217" pm="."><plain>6HampelH.AbrahamN. </plain></SENT>
<SENT sid="218" pm="."><plain>S.El-SeragH. </plain></SENT>
<SENT sid="219" pm="."><plain>B.Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complicationsAnnals of Internal Medicine2005143319921110.7326/0003-4819-143-3-200508020-000062-s2.0-2304449320216061918 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="220" pm="."><plain>7CunninghamD.StarlingN.RaoS.Capecitabine and oxaliplatin for advanced esophagogastric cancerThe New England Journal of Medicine20083581364610.1056/nejmoa0731492-s2.0-3804904717818172173 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="221" pm="."><plain>8OvermanM. </plain></SENT>
<SENT sid="222" pm="."><plain>J.KazmiS. </plain></SENT>
<SENT sid="223" pm="."><plain>M.JhambJ.Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancerCancer201011661446145310.1002/cncr.249252-s2.0-7794941496420108336 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="224" pm="."><plain>9TebbuttN. </plain></SENT>
<SENT sid="225" pm="."><plain>C.CumminsM. </plain></SENT>
<SENT sid="226" pm="."><plain>M.SourjinaT.Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trialBritish Journal of Cancer2010102347548110.1038/sj.bjc.66055222-s2.0-7634908803920068567 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="227" pm="."><plain>10ShahM. </plain></SENT>
<SENT sid="228" pm="."><plain>A.ShibataS.StollerR. </plain></SENT>
<SENT sid="229" pm="."><plain>G.Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE)28ASCO Meeting Abstracts2014p. </plain></SENT>
<SENT sid="230" pm="."><plain>4014 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="231" pm="."><plain>11FordH. </plain></SENT>
<SENT sid="232" pm="."><plain>E. </plain></SENT>
<SENT sid="233" pm="."><plain>R.MarshallA.BridgewaterJ. </plain></SENT>
<SENT sid="234" pm="."><plain>A.Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trialThe Lancet Oncology201415178862-s2.0-8489137115610.1016/s1470-2045(13)70549-724332238 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="235" pm="."><plain>12KimH. </plain></SENT>
<SENT sid="236" pm="."><plain>S.KimH. </plain></SENT>
<SENT sid="237" pm="."><plain>J.KimS. </plain></SENT>
<SENT sid="238" pm="."><plain>Y.Second-line chemotherapy versus supportive cancertreatment in advanced gastric cancer: a meta-analysisAnnals of Oncology201324112850285410.1093/annonc/mdt3512-s2.0-8488711645523942775 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="239" pm="."><plain>13HawkesE.OkinesA. </plain></SENT>
<SENT sid="240" pm="."><plain>F. </plain></SENT>
<SENT sid="241" pm="."><plain>C.PapamichaelD.Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancerEuropean Journal of Cancer2011478114611512-s2.0-7995553422710.1016/j.ejca.2010.12.02121269822 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="242" pm="."><plain>14HironakaS.ZendaS.BokuN.FukutomiA.YoshinoT.OnozawaY.Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancerGastric Cancer20069114182-s2.0-3364523564510.1007/s10120-005-0351-616557431 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="243" pm="."><plain>15BoussioutasA.LiH.LiuJ.Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancerCancer Research20036310256925772-s2.0-003857635212750281 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="244" pm="."><plain>16TanI. </plain></SENT>
<SENT sid="245" pm="."><plain>B.IvanovaT.LimK. </plain></SENT>
<SENT sid="246" pm="."><plain>H.Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapyGastroenterology20111412476485, 485 e1–1110.1053/j.gastro.2011.04.0422-s2.0-8005148683421684283 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="247" pm="."><plain>17LeiZ.TanI. </plain></SENT>
<SENT sid="248" pm="."><plain>B.DasK.Identification of molecular subtypes of gastric cancer with different responses to pi3-kinase inhibitors and 5-fluorouracilGastroenterology2013145355456510.1053/j.gastro.2013.05.0102-s2.0-8488318576623684942 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="249" pm="."><plain>18The Cancer Genome Atlas Research NetworkComprehensive molecular characterization of gastric adenocarcinomaNature2014513751720220910.1038/nature1348025079317 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="250" pm="."><plain>19GuJ.AjaniJ. </plain></SENT>
<SENT sid="251" pm="."><plain>A.HawkE. </plain></SENT>
<SENT sid="252" pm="."><plain>T.Genome-wide catalogue of chromosomal aberrations in Barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysisCancer Prevention Research201039117611862-s2.0-7795640213010.1158/1940-6207.capr-09-026520651033 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="253" pm="."><plain>20VarisA.PuolakkainenP.SavolainenH.DNA copy number profiling in esophageal Barrett adenocarcinoma: comparison with gastric adenocarcinoma and esophageal squamous cell carcinomaCancer Genetics and Cytogenetics20011271535810.1016/s0165-4608(00)00423-42-s2.0-003533365411408066 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="254" pm="."><plain>21ReidB. </plain></SENT>
<SENT sid="255" pm="."><plain>J.PrevoL. </plain></SENT>
<SENT sid="256" pm="."><plain>J.GalipeauP. </plain></SENT>
<SENT sid="257" pm="."><plain>C.Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progressionThe American Journal of Gastroenterology200196102839284810.1016/s0002-9270(01)02798-82-s2.0-003479384611693316 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="258" pm="."><plain>22HollsteinM. </plain></SENT>
<SENT sid="259" pm="."><plain>C.MetcalfR. </plain></SENT>
<SENT sid="260" pm="."><plain>A.WelshJ. </plain></SENT>
<SENT sid="261" pm="."><plain>A.MontesanoR.HarrisC. </plain></SENT>
<SENT sid="262" pm="."><plain>C.Frequent mutation of the p53 gene in human esophageal cancerProceedings of the National Academy of Sciences of the United States of America199087249958996110.1073/pnas.87.24.99582-s2.0-00255999282263646 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="263" pm="."><plain>23CassonA. </plain></SENT>
<SENT sid="264" pm="."><plain>G.MukhopadhyayT.ClearyK. </plain></SENT>
<SENT sid="265" pm="."><plain>R.RoJ. </plain></SENT>
<SENT sid="266" pm="."><plain>Y.LevinB.RothJ. </plain></SENT>
<SENT sid="267" pm="."><plain>A.p53 gene mutations in Barrett's epithelium and esophageal cancerCancer Research19915116449544992-s2.0-00259894681868473 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="268" pm="."><plain>24PowellE. </plain></SENT>
<SENT sid="269" pm="."><plain>L.LeoniL. </plain></SENT>
<SENT sid="270" pm="."><plain>M.CantoM. </plain></SENT>
<SENT sid="271" pm="."><plain>I.Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implicationsThe American Journal of Surgical Pathology20052911149715042-s2.0-2724444930710.1097/01.pas.0000170349.47680.e816224217 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="272" pm="."><plain>25AbeloffM. </plain></SENT>
<SENT sid="273" pm="."><plain>D.EgglestonJ. </plain></SENT>
<SENT sid="274" pm="."><plain>C.MendelsohnG.EttingerD. </plain></SENT>
<SENT sid="275" pm="."><plain>S.BaylinS. </plain></SENT>
<SENT sid="276" pm="."><plain>B.Changes in morphologic and biochemical characteristics of small cell carcinoma of the lung. </plain></SENT>
<SENT sid="277" pm="."><plain>A clinicopathologic studyThe American Journal of Medicine19796657577642-s2.0-001877712110.1016/0002-9343(79)91113-6220872 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="278" pm="."><plain>26AgrawalN.JiaoY.BettegowdaC.Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinomaCancer Discovery201221089990510.1158/2159-8290.CD-12-01892-s2.0-8486739821722877736 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="279" pm="."><plain>27DulakA. </plain></SENT>
<SENT sid="280" pm="."><plain>M.SchumacherS. </plain></SENT>
<SENT sid="281" pm="."><plain>E.van LieshoutJ.Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesisCancer Research201272174383439310.1158/0008-5472.can-11-38932-s2.0-8486523893622751462 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="282" pm="."><plain>28OlayioyeM. </plain></SENT>
<SENT sid="283" pm="."><plain>A.Update on HER-2 as a target for cancer therapy—intracellular signaling pathways of ErbB2/HER-2 and family membersBreast Cancer Research20013638538910.1186/bcr3272-s2.0-234248896511737890 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="284" pm="."><plain>29TannerM.HollménM.JunttilaT. </plain></SENT>
<SENT sid="285" pm="."><plain>T.Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumabAnnals of Oncology20051622732782-s2.0-2004437272110.1093/annonc/mdi06415668283 </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="286" pm="."><plain>30ParkD. </plain></SENT>
<SENT sid="287" pm="."><plain>I.YunJ. </plain></SENT>
<SENT sid="288" pm="."><plain>W.ParkJ. </plain></SENT>
<SENT sid="289" pm="."><plain>H.HER-2/neu amplification is an independent prognostic factor in gastric cancerDigestive Diseases and Sciences20065181371137910.1007/s10620-005-9057-116868827 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="290" pm="."><plain>31JanjigianY. </plain></SENT>
<SENT sid="291" pm="."><plain>Y.WernerD.PauligkC.Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysisAnnals of Oncology201223102656266210.1093/annonc/mds1042-s2.0-8486713157922689179 </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="292" pm="."><plain>32Gómez-MartinC.GarraldaE.EcharriM. </plain></SENT>
<SENT sid="293" pm="."><plain>J.HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancerJournal of Clinical Pathology201265875175710.1136/jclinpath-2012-2007742-s2.0-8486455175622569536 </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="294" pm="."><plain>33BangY.-J.Van CutsemE.FeyereislovaA.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2- positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet2010376974268769710.1016/S0140-6736(10)61121-X2-s2.0-77958099652 </plain></SENT>
</text></ref><ref id="B34"><text><SENT sid="295" pm="."><plain>34GoldhirschA.GelberR. </plain></SENT>
<SENT sid="296" pm="."><plain>D.Piccart-GebhartM. </plain></SENT>
<SENT sid="297" pm="."><plain>J.2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trialThe Lancet201338298971021102810.1016/s0140-6736(13)61094-62-s2.0-84884418164 </plain></SENT>
</text></ref><ref id="B35"><text><SENT sid="298" pm="."><plain>35von MinckwitzG.SchwedlerK.SchmidtM.Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancerEuropean Journal of Cancer201147152273228110.1016/j.ejca.2011.06.0212-s2.0-8005336229021741829 </plain></SENT>
</text></ref><ref id="B36"><text><SENT sid="299" pm="."><plain>36SakaiD.SatohT.KurokawaY.A phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1203 (HERBIS-5)Japanese Journal of Clinical Oncology201343883884010.1093/jjco/hyt0832-s2.0-8488108965923852648 </plain></SENT>
</text></ref><ref id="B37"><text><SENT sid="300" pm="."><plain>37WoodE. </plain></SENT>
<SENT sid="301" pm="."><plain>R.TruesdaleA. </plain></SENT>
<SENT sid="302" pm="."><plain>T.McDonaldO. </plain></SENT>
<SENT sid="303" pm="."><plain>B.A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cellsCancer Research20046418665266592-s2.0-464428931310.1158/0008-5472.can-04-116815374980 </plain></SENT>
</text></ref><ref id="B38"><text><SENT sid="304" pm="."><plain>38SatohT.XuR.-H.ChungH. </plain></SENT>
<SENT sid="305" pm="."><plain>C.Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN–a randomized, phase III studyJournal of Clinical Oncology201432192039204910.1200/jco.2013.53.613624868024 </plain></SENT>
</text></ref><ref id="B39"><text><SENT sid="306" pm="."><plain>39AdamsC. </plain></SENT>
<SENT sid="307" pm="."><plain>W.AllisonD. </plain></SENT>
<SENT sid="308" pm="."><plain>E.FlagellaK.Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumabCancer Immunology, Immunotherapy200655671772710.1007/s00262-005-0058-x2-s2.0-3364460048516151804 </plain></SENT>
</text></ref><ref id="B40"><text><SENT sid="309" pm="."><plain>40TaberneroJ.Marcelo HoffP.ShenL.Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: an international phase III study (JACOB)Journal of Clinical Oncology2013abstr TPS4150 </plain></SENT>
</text></ref><ref id="B41"><text><SENT sid="310" pm="."><plain>41LoRussoP. </plain></SENT>
<SENT sid="311" pm="."><plain>M.WeissD.GuardinoE.GirishS.SliwkowskiM. </plain></SENT>
<SENT sid="312" pm="."><plain>X.Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancerClinical Cancer Research201117206437644710.1158/1078-0432.ccr-11-07622-s2.0-8005409298322003071 </plain></SENT>
</text></ref><ref id="B42"><text><SENT sid="313" pm="."><plain>42EricksonH. </plain></SENT>
<SENT sid="314" pm="."><plain>K.ParkP. </plain></SENT>
<SENT sid="315" pm="."><plain>U.WiddisonW. </plain></SENT>
<SENT sid="316" pm="."><plain>C.Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processingCancer Research20066684426443310.1158/0008-5472.CAN-05-44892-s2.0-3364550028916618769 </plain></SENT>
</text></ref><ref id="B43"><text><SENT sid="317" pm="."><plain>43UK Clinical Research Network Study PortfolioNCRN369: GATSBY TDM1 vs taxane in previously treated advanced HER2+ gastric caUKCRN12204<ext-link ext-link-type="uri" xlink:href="http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=12204">http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=12204</ext-link> </plain></SENT>
</text></ref><ref id="B44"><text><SENT sid="318" pm="."><plain>44MuthuswamyS. </plain></SENT>
<SENT sid="319" pm="."><plain>K.GilmanM.BruggeJ. </plain></SENT>
<SENT sid="320" pm="."><plain>S.Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimersMolecular and Cellular Biology19991910684568572-s2.0-003286081910490623 </plain></SENT>
</text></ref><ref id="B45"><text><SENT sid="321" pm="."><plain>45ChenC.YangJ.-M.HuT.-T.Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysisArchives of Medical Research201344538038910.1016/j.arcmed.2013.07.0012-s2.0-8488340135823871709 </plain></SENT>
</text></ref><ref id="B46"><text><SENT sid="322" pm="."><plain>46ZhangL.YangJ.CaiJ.A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapyScientific Reports20133, article 299210.1038/srep029922-s2.0-84886299562 </plain></SENT>
</text></ref><ref id="B47"><text><SENT sid="323" pm="."><plain>47Van CutsemE.KöhneC.-H.LángI.Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation statusJournal of Clinical Oncology201129152011201910.1200/jco.2010.33.50912-s2.0-7995629881221502544 </plain></SENT>
</text></ref><ref id="B48"><text><SENT sid="324" pm="."><plain>48LordickF.KangY.-K.ChungH.-C.Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trialThe Lancet Oncology20131464904992-s2.0-8487695176110.1016/s1470-2045(13)70102-523594786 </plain></SENT>
</text></ref><ref id="B49"><text><SENT sid="325" pm="."><plain>49WaddellT.ChauI.CunninghamD.Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialThe Lancet Oncology20131464814892-s2.0-8487699249810.1016/s1470-2045(13)70096-223594787 </plain></SENT>
</text></ref><ref id="B50"><text><SENT sid="326" pm="."><plain>50RaoS.StarlingN.CunninghamD.Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II studyAnnals of Oncology20102111221322192-s2.0-7795849660510.1093/annonc/mdq24720497967 </plain></SENT>
</text></ref><ref id="B51"><text><SENT sid="327" pm="."><plain>51InoueT.KataokaH.GotoK.Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissueCancer Science2004951080380810.1111/j.1349-7006.2004.tb02185.x2-s2.0-914425103615504247 </plain></SENT>
</text></ref><ref id="B52"><text><SENT sid="328" pm="."><plain>52ConrottoP.ValdembriD.CorsoS.Sema4D induces angiogenesis through Met recruitment by Plexin B1Blood200510511432143292-s2.0-1934436459810.1182/blood-2004-07-288515632204 </plain></SENT>
</text></ref><ref id="B53"><text><SENT sid="329" pm="."><plain>53HuangT.-J.WangJ.-Y.LinS.-R.LianS.-T.HsiehJ.-S.Overexpression of the c-met protooncogene in human gastric carcinoma—correlation to clinical featuresActa Oncologica200140563864310.1080/0284186017504442042-s2.0-003478909611669338 </plain></SENT>
</text></ref><ref id="B54"><text><SENT sid="330" pm="."><plain>54YuS.YuY.ZhaoN.CuiJ.LiW.LiuT.c-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysisPLoS ONE2013811e7913710.1371/journal.pone.00791372-s2.0-84892394160 </plain></SENT>
</text></ref><ref id="B55"><text><SENT sid="331" pm="."><plain>55IvesonT.DonehowerR. </plain></SENT>
<SENT sid="332" pm="."><plain>C.DavidenkoI.Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 studyThe Lancet Oncology20141591007101810.1016/s1470-2045(14)70023-324965569 </plain></SENT>
</text></ref><ref id="B56"><text><SENT sid="333" pm="."><plain>56A Phase 3 Study of Rilotumumab (AMG 102) with Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer (RILOMET-2), NCT02137343, 2014, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT02137343">http://clinicaltrials.gov/show/NCT02137343</ext-link> </plain></SENT>
</text></ref><ref id="B57"><text><SENT sid="334" pm="."><plain>57CallesA.KwiatkowskiN.CammarataB. </plain></SENT>
<SENT sid="335" pm="."><plain>K.ErcanD.GrayN. </plain></SENT>
<SENT sid="336" pm="."><plain>S.JänneP. </plain></SENT>
<SENT sid="337" pm="."><plain>A.Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell linesMolecular Oncology20159126026910.1016/j.molonc.2014.08.01125226813 </plain></SENT>
</text></ref><ref id="B58"><text><SENT sid="338" pm="."><plain>58KatayamaR.AoyamaA.YamoriT.Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibitionCancer Research201373103087309610.1158/0008-5472.can-12-32562-s2.0-8487784858723598276 </plain></SENT>
</text></ref><ref id="B59"><text><SENT sid="339" pm="."><plain>59KangY.-K.MuroK.RyuM.-H.A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancerInvestigational New Drugs201432235536110.1007/s10637-013-0057-22-s2.0-8489640476424337769 </plain></SENT>
</text></ref><ref id="B60"><text><SENT sid="340" pm="."><plain>60FerraraN.GerberH.-P.LeCouterJ.The biology of VEGF and its receptorsNature Medicine20039666967610.1038/nm0603-6692-s2.0-0037699954 </plain></SENT>
</text></ref><ref id="B61"><text><SENT sid="341" pm="."><plain>61ShahM. </plain></SENT>
<SENT sid="342" pm="."><plain>A.RamanathanR. </plain></SENT>
<SENT sid="343" pm="."><plain>K.IlsonD. </plain></SENT>
<SENT sid="344" pm="."><plain>H.Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinomaJournal of Clinical Oncology200624335201520610.1200/jco.2006.08.08872-s2.0-3384662967217114652 </plain></SENT>
</text></ref><ref id="B62"><text><SENT sid="345" pm="."><plain>62ShahM. </plain></SENT>
<SENT sid="346" pm="."><plain>A.Van CutsemE.KangY. </plain></SENT>
<SENT sid="347" pm="."><plain>K.Survival analysis according to disease subtype in AVAGAST: first-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancerJournal of Clinical Oncology201230supplement 4, abstract 5 </plain></SENT>
</text></ref><ref id="B63"><text><SENT sid="348" pm="."><plain>63OhtsuA.ShahM. </plain></SENT>
<SENT sid="349" pm="."><plain>A.van CutsemE.Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III studyJournal of Clinical Oncology201129303968397610.1200/jco.2011.36.22362-s2.0-8005357344621844504 </plain></SENT>
</text></ref><ref id="B64"><text><SENT sid="350" pm="."><plain>64FuchsC. </plain></SENT>
<SENT sid="351" pm="."><plain>S.TomasekJ.YongC. </plain></SENT>
<SENT sid="352" pm="."><plain>J.Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trialThe Lancet2014383991131392-s2.0-8489285237210.1016/s0140-6736(13)61719-5 </plain></SENT>
</text></ref><ref id="B65"><text><SENT sid="353" pm="."><plain>65WilkeH.van CutsemE.OhS. </plain></SENT>
<SENT sid="354" pm="."><plain>C.RAINBOW: a global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE)Journal of Clinical Oncology201432supplement 3Gastrointestinal Cancers Symposium abstract no. LBA7 </plain></SENT>
</text></ref><ref id="B66"><text><SENT sid="355" pm="."><plain>66YoonH. </plain></SENT>
<SENT sid="356" pm="."><plain>H.BendellJ. </plain></SENT>
<SENT sid="357" pm="."><plain>C.BraitehF. </plain></SENT>
<SENT sid="358" pm="."><plain>S.Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): randomized, double-blind, multicenter phase 2 trialJournal of Clinical Oncology2014325sabstr 4004 </plain></SENT>
</text></ref><ref id="B67"><text><SENT sid="359" pm="."><plain>67BangY.-J.KangY.-K.KangW. </plain></SENT>
<SENT sid="360" pm="."><plain>K.Phase II study of sunitinib as second-line treatment for advanced gastric cancerInvestigational New Drugs20112961449145810.1007/s10637-010-9438-y2-s2.0-8295524198520461441 </plain></SENT>
</text></ref><ref id="B68"><text><SENT sid="361" pm="."><plain>68YiJ. </plain></SENT>
<SENT sid="362" pm="."><plain>H.LeeJ.LeeJ.Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinumBritish Journal of Cancer201210691469147410.1038/bjc.2012.1002-s2.0-8486023433022460270 </plain></SENT>
</text></ref><ref id="B69"><text><SENT sid="363" pm="."><plain>69Martin-RichardM.GallegoR.PericayC.Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. </plain></SENT>
<SENT sid="364" pm="."><plain>A GEMCAD studyInvestigational New Drugs20133161573157910.1007/s10637-013-0020-22-s2.0-8488862765224077981 </plain></SENT>
</text></ref><ref id="B70"><text><SENT sid="365" pm="."><plain>70WongD. </plain></SENT>
<SENT sid="366" pm="."><plain>J.SegalE.ChangH. </plain></SENT>
<SENT sid="367" pm="."><plain>Y.Stemness, cancer and cancer stem cellsCell Cycle20087233622362410.4161/cc.7.23.71042-s2.0-5734910709419029796 </plain></SENT>
</text></ref><ref id="B71"><text><SENT sid="368" pm="."><plain>71HitronM.StephensonJ.ChiK. </plain></SENT>
<SENT sid="369" pm="."><plain>N.A phase 1b study of the cancer stem cell inhibitor BBI608 administered with paclitaxel in patients with advanced malignanciesJournal of Clinical Oncology201432supplement, abstract 2530 </plain></SENT>
</text></ref><ref id="B72"><text><SENT sid="370" pm="."><plain>72BaiR.ZhaoH.ZhangX.DuS.Characterization of sonic hedgehog inhibition in gastric carcinoma cellsOncology Letters2014751381138410.3892/ol.2014.19642-s2.0-8489627722424765141 </plain></SENT>
</text></ref><ref id="B73"><text><SENT sid="371" pm="."><plain>73CohenD. </plain></SENT>
<SENT sid="372" pm="."><plain>J.ChristosP. </plain></SENT>
<SENT sid="373" pm="."><plain>J.SparanoJ. </plain></SENT>
<SENT sid="374" pm="."><plain>A.A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: a New York Cancer Consortium led studyJournal of Clinical Oncology201331supplement 4, abstract 67 </plain></SENT>
</text></ref><ref id="B74"><text><SENT sid="375" pm="."><plain>74YoonC.ParkD. </plain></SENT>
<SENT sid="376" pm="."><plain>J.SchmidtB.CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistanceClinical Cancer Research201420153974398810.1158/1078-0432.ccr-14-001124947926 </plain></SENT>
</text></ref><ref id="B75"><text><SENT sid="377" pm="."><plain>75PavelićK.KolakT.KapitanovićS.Gastric cancer: the role of insulin-like growth factor 2 (IGF 2) and its receptors (IGF IR and M6-P/IGF 2R)The Journal of Pathology2003201343043810.1002/path.14652-s2.0-024255894214595755 </plain></SENT>
</text></ref><ref id="B76"><text><SENT sid="378" pm="."><plain>76GaoJ.ChangY. </plain></SENT>
<SENT sid="379" pm="."><plain>S.JallalB.VinerJ.Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncologyCancer Research201272131210.1158/0008-5472.can-11-05502-s2.0-8485539882922215692 </plain></SENT>
</text></ref><ref id="B77"><text><SENT sid="380" pm="."><plain>77SchöffskiP.AdkinsD.BlayJ.-Y.An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumoursEuropean Journal of Cancer201349153219322810.1016/j.ejca.2013.06.0102-s2.0-8488491010723835252 </plain></SENT>
</text></ref><ref id="B78"><text><SENT sid="381" pm="."><plain>78CohenS. </plain></SENT>
<SENT sid="382" pm="."><plain>J.FengY.CatalanoP. </plain></SENT>
<SENT sid="383" pm="."><plain>J.E2208: randomized phase II study of paclitaxel with or without the anti-IGF-IR antibody cixutumumab (IMC-A12) as second-line treatment for patients with metastatic esophageal or GE junction cancerJournal of Clinical Oncology2014325, supplementASCO Annual Meeting abstract no. 4020 </plain></SENT>
</text></ref><ref id="B79"><text><SENT sid="384" pm="."><plain>79BarrF. </plain></SENT>
<SENT sid="385" pm="."><plain>A.SilljéH. </plain></SENT>
<SENT sid="386" pm="."><plain>H. </plain></SENT>
<SENT sid="387" pm="."><plain>W.NiggE. </plain></SENT>
<SENT sid="388" pm="."><plain>A.Polo-like kinases and the orchestration of cell divisionNature Reviews Molecular Cell Biology2004564294402-s2.0-294261528215173822 </plain></SENT>
</text></ref><ref id="B80"><text><SENT sid="389" pm="."><plain>80Spänkuch-SchmittB.WolfG.SolbachC.Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cellsOncogene200221203162317110.1038/sj/onc/12054122-s2.0-003704649512082631 </plain></SENT>
</text></ref><ref id="B81"><text><SENT sid="390" pm="."><plain>81WeichertW.UllrichA.SchmidtM.Expression patterns of polo-like kinase 1 in human gastric cancerCancer Science200697427127610.1111/j.1349-7006.2006.00170.x2-s2.0-3364534034816630118 </plain></SENT>
</text></ref><ref id="B82"><text><SENT sid="391" pm="."><plain>82de BraudF. </plain></SENT>
<SENT sid="392" pm="."><plain>G.CascinuS.SpitaleriG.A phase I dose-escalation study of volasertib (BI 6727) combined with nintedanib (BIBF 1120) in advanced solid tumorsJournal of Clinical Oncology201331supplement, abstract 2556 </plain></SENT>
</text></ref><ref id="B83"><text><SENT sid="393" pm="."><plain>83KatohM.FGF signaling network in the gastrointestinal tract (review)International Journal of Oncology20062911631682-s2.0-3375111343916773196 </plain></SENT>
</text></ref><ref id="B84"><text><SENT sid="394" pm="."><plain>84MuraseH.InokuchiM.TakagiY.KatoK.KojimaK.SugiharaK.Prognostic significance of the co-overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancerMolecular and Clinical Oncology20142450951724940486 </plain></SENT>
</text></ref><ref id="B85"><text><SENT sid="395" pm="."><plain>85Dovitinib for Gastric Cancer With FGFR2 Amplification, NCT01719549, 2014, <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT01719549?term=fgf+gastric&amp;rank=1">http://www.clinicaltrials.gov/ct2/show/NCT01719549?term=fgf+gastric&amp;rank=1</ext-link> </plain></SENT>
</text></ref><ref id="B86"><text><SENT sid="396" pm="."><plain>86Fresno VaraJ. </plain></SENT>
<SENT sid="397" pm="."><plain>A.CasadoE.de CastroJ.CejasP.Belda-IniestaC.González-BarónM.PI3K/Akt signalling pathway and cancerCancer Treatment Reviews200430219320410.1016/j.ctrv.2003.07.00715023437 </plain></SENT>
</text></ref><ref id="B87"><text><SENT sid="398" pm="."><plain>87ManningB. </plain></SENT>
<SENT sid="399" pm="."><plain>D.CantleyL. </plain></SENT>
<SENT sid="400" pm="."><plain>C.AKT/PKB signaling: navigating downstreamCell200712971261127410.1016/j.cell.2007.06.0092-s2.0-3425078880917604717 </plain></SENT>
</text></ref><ref id="B88"><text><SENT sid="401" pm="."><plain>88FingarD. </plain></SENT>
<SENT sid="402" pm="."><plain>C.RichardsonC. </plain></SENT>
<SENT sid="403" pm="."><plain>J.TeeA. </plain></SENT>
<SENT sid="404" pm="."><plain>R.CheathamL.TsouC.BlenisJ.mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4EMolecular and Cellular Biology200424120021610.1128/mcb.24.1.200-216.20042-s2.0-034573264014673156 </plain></SENT>
</text></ref><ref id="B89"><text><SENT sid="405" pm="."><plain>89MurayamaT.InokuchiM.TakagiY.Relation between outcomes and localisation of p-mTOR expression in gastric cancerBritish Journal of Cancer2009100578278810.1038/sj.bjc.66049152-s2.0-6174908580319223902 </plain></SENT>
</text></ref><ref id="B90"><text><SENT sid="406" pm="."><plain>90VelhoS.OliveiraC.FerreiraA.The prevalence of PIK3CA mutations in gastric and colon cancerEuropean Journal of Cancer200541111649165410.1016/j.ejca.2005.04.0222-s2.0-2214445250715994075 </plain></SENT>
</text></ref><ref id="B91"><text><SENT sid="407" pm="."><plain>91SukawaY.YamamotoH.NoshoK.Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancerWorld Journal of Gastroenterology201218456577658610.3748/wjg.v18.i45.65772-s2.0-8487388575323236232 </plain></SENT>
</text></ref><ref id="B92"><text><SENT sid="408" pm="."><plain>92LiM.SunH.SongL.GaoX.ChangW.QinX.Immunohistochemical expression of mTOR negatively correlates with PTEN expression in gastric carcinomaOncology Letters2012461213121810.3892/ol.2012.9302-s2.0-8486725368223205120 </plain></SENT>
</text></ref><ref id="B93"><text><SENT sid="409" pm="."><plain>93PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer, NCT01613950, 2014, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT01613950">http://clinicaltrials.gov/show/NCT01613950</ext-link> </plain></SENT>
</text></ref><ref id="B94"><text><SENT sid="410" pm="."><plain>94OhtsuA.AjaniJ. </plain></SENT>
<SENT sid="411" pm="."><plain>A.BaiY.-X.Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 studyJournal of Clinical Oncology201331313935394310.1200/jco.2012.48.35522-s2.0-8489137139224043745 </plain></SENT>
</text></ref><ref id="B95"><text><SENT sid="412" pm="."><plain>95RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer, NCT01049620, 2014, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT01049620?term=pi3k+gastric&amp;rank=3">http://clinicaltrials.gov/ct2/show/NCT01049620?term=pi3k+gastric&amp;rank=3</ext-link> </plain></SENT>
</text></ref><ref id="B96"><text><SENT sid="413" pm="."><plain>96A Randomized, Double Blind Study Evaluating Paclitaxel with and without RAD001 in Patients with Gastric Carcinoma After Prior Chemotherapy (AIO-STO-0111), NCT01248403, 2014, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT01248403">http://clinicaltrials.gov/show/NCT01248403</ext-link> </plain></SENT>
</text></ref><ref id="B97"><text><SENT sid="414" pm="."><plain>97PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma—A 1st Pilot Metastatic Trial of Biologics Beyond Progression, NCT02213289, 2014, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT02213289">http://clinicaltrials.gov/show/NCT02213289</ext-link> </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="FIG"><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p><text><SENT sid="415" pm="."><plain>(a) Molecular classification of gastric adenocarcinomas. </plain></SENT>
<SENT sid="416" pm="."><plain>Primary gastric adenocarcinomas (n = 295) were analyzed in the TCGA project and found to have four main subtypes: CIN (chromosomal instability) 49.8%, GS (genomically stable) 19.6%, MSI (microsatellite instability) 21.7%, and EBV (Epstein-Barr virus), positive 8.8%. </plain></SENT>
<SENT sid="417" pm="."><plain>Adapted from data in TCGA [18]. </plain></SENT>
<SENT sid="418" pm="."><plain>(b) Characteristics of molecular subtypes of gastric cancer. </plain></SENT>
<SENT sid="419" pm="."><plain>Adapted from data in TCGA [18]. </plain></SENT>
<SENT sid="420" pm="."><plain>The key features of each molecular subtype are listed adjacent to the representation of subtype. </plain></SENT>
</text></p></caption><graphic xlink:href="GRP2015-896560.001"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p><text><SENT sid="421" pm="."><plain>Current and recently completed phase III trials in gastric and gastroesophageal junction cancer. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="422" pm="."><plain>Agent </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="423" pm="."><plain>Clinical trial </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="424" pm="."><plain>Randomization </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="425" pm="."><plain>n </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="426" pm="."><plain>NCT identifier </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="427" pm="."><plain>HER2 inhibitors </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="428" pm="."><plain>Pertuzumab </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="429" pm="."><plain>JACOB </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="430" pm="."><plain>Pertuzumab in combination with Herceptin and chemotherapy </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="431" pm="."><plain>780 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="432" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01774786">NCT01774786</ext-link> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="433" pm="."><plain>T-DM1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="434" pm="."><plain>GATSBY </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="435" pm="."><plain>T-DM1 with or without taxane. </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="436" pm="."><plain>412 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="437" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01641939">NCT01641939</ext-link> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="438" pm="."><plain>Trastuzumab </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="439" pm="."><plain>HELOISE </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="440" pm="."><plain>XP-T (standard versus high-dose) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="441" pm="."><plain>400 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="442" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01450696">NCT01450696</ext-link> </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="443" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="444" pm="."><plain>MET pathway inhibitors </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="445" pm="."><plain>Rilotumumab </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="446" pm="."><plain>RILOMET-2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="447" pm="."><plain>XP with or without rilotumumab </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="448" pm="."><plain>450 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="449" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT02137343">NCT02137343</ext-link> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="450" pm="."><plain>Rilotumumab </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="451" pm="."><plain>RILOMET-1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="452" pm="."><plain>ECX with or without rilotumumab </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="453" pm="."><plain>600 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="454" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01697072">NCT01697072</ext-link> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="455" pm="."><plain>Onartuzumab </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="456" pm="."><plain>METGASTRIC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="457" pm="."><plain>FOLFOX with or without onartuzumab </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="458" pm="."><plain>800 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="459" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01662869">NCT01662869</ext-link> </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="460" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="461" pm="."><plain>Cancer stemness inhibitor </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="462" pm="."><plain>BBI608 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="463" pm="."><plain>BRIGHTER </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="464" pm="."><plain>Paclitaxel with or without BBI608 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="465" pm="."><plain>680 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="466" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02178956">NCT02178956</ext-link> </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="467" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="468" pm="."><plain>EGFR inhibitors </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="469" pm="."><plain>Panitumumab </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="470" pm="."><plain>REAL-3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="471" pm="."><plain>EOX with or without panitumumab </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="472" pm="."><plain>574 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="473" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00824785">NCT00824785</ext-link> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="474" pm="."><plain>Cetuximab </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="475" pm="."><plain>EXPAND </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="476" pm="."><plain>XP with or without cetuximab </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="477" pm="."><plain>904 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="478" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00678535">NCT00678535</ext-link> </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="479" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="480" pm="."><plain>Angiogenesis inhibitors </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="481" pm="."><plain>Ramucirumab </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="482" pm="."><plain>REGARD </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="483" pm="."><plain>Ramucirumab versus BSC </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="484" pm="."><plain>355 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="485" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00917384">NCT00917384</ext-link> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="486" pm="."><plain>Ramucirumab </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="487" pm="."><plain>RAINBOW </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="488" pm="."><plain>Paclitaxel with or without ramucirumab </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="489" pm="."><plain>665 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="490" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01170663">NCT01170663</ext-link> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="491" pm="."><plain>Regorafenib </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="492" pm="."><plain>INTEGRATE </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="493" pm="."><plain>Regorafenib versus BSC </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="494" pm="."><plain>150 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="495" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12612000239864">Actrn12612000239864</ext-link> </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p>T-DM1: trastuzumab emtansine; XP: cisplatin, capecitabine; XP-T: cisplatin, capecitabine; T: trastuzumab; ECX: epirubicin, cisplatin, and capecitabine; FOLFOX: 5FU, folinic acid, and oxaliplatin; EOX: epirubicin, oxaliplatin, and capecitabine; BSC: best supportive care. </p></fn></table-wrap-foot></table-wrap></SecTag></floats-group></article>
